Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(11%)
Results Posted
100%(2 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
6
67%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)
Other(3)

Detailed Status

unknown3
Completed2
Recruiting1
Not yet recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

recruiting111%
not_yet_recruiting111%
unknown333%
terminated111%
completed222%
withdrawn111%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

NCT02269280
not_yet_recruitingphase_2

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

NCT07052422
recruitingphase_2

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

NCT06686108
terminatedphase_1

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724
unknownphase_2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

NCT05453552
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02269280Phase 2

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Completed
NCT07052422Phase 2

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not Yet Recruiting
NCT06686108Phase 2

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Recruiting
NCT03233724Phase 1

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Terminated
NCT05453552Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Unknown
NCT05449899Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Unknown
NCT04713956Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Unknown
NCT00002831Phase 1

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Completed
NCT02839694Phase 1

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9